Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Monoclonal Antibodies Active Trials in China
As of 2026-09-04, there are 18 active clinical trials investigating Monoclonal Antibodies for multiple myeloma across 29 provinces and 217 study centers in China. Monoclonal antibodies bind a single antigen on the myeloma cell surface — CD38 being the dominant target in China — and eliminate tumour cells through antibody-dependent cytotoxicity and complement activation. They are a common backbone in both frontline and relapsed regimens.
Active Studies (18)
Population synthesized by CMDNShowing 4 published English records of 18 registry trials.